Resmed Inc Dossier
Qualitative Analysis
Business overview
ResMed Inc. is a global leader in the development, manufacturing, and commercialization of medical devices and cloud-connected software solutions for sleep and respiratory care. The company operates primarily through two segments: Sleep and Breathing Health (which includes CPAP devices, masks, and accessories) and Residential Care Software (RCS). ResMed's hardware products, such as the AirSense 11 platform, are deeply integrated with its digital health ecosystem, including the AirView and myAir platforms, which manage over 30 million and 11 million patients respectively. This connected-care model enhances patient compliance, remote monitoring workflows, and therapy adherence. ResMed markets its solutions in over 140 countries, maintaining a highly diversified global manufacturing and distribution footprint.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A long-term strategic roadmap focused on accelerating product and technology innovation, operational excellence, commercial execution, and digital ecosystem integration to help more than 500 million people achieve their full health potential by 2030.
Expected impact: Aims to drive high single-digit revenue growth and double-digit operating profit growth, expanding the core sleep apnea franchise and building a robust data moat through cloud-connected devices.
Strategic investments in domestic manufacturing and distribution facilities, including the opening of a $30 million facility in Calabasas, California, and the development of a new facility in Indianapolis, Indiana.
Expected impact: Doubles the US manufacturing footprint, secures supply chain resilience against geopolitical uncertainties, and optimizes logistics to reach 90% of US customers within two business days.
A comprehensive brand consolidation initiative to unify ResMed's diverse portfolio of brands, products, and services under a single, cohesive ResMed identity.
Expected impact: Simplifies the customer experience for both consumers and healthcare providers, destigmatizes CPAP therapy through consumer campaigns, and drives earlier diagnosis via primary care physician education.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Expands ResMed's clinical sleep health portfolio into Restless Legs Syndrome (RLS), the third most prevalent sleep disorder, by adding the FDA De Novo classified Nidra Tonic Motor Activation (TOMAC) Therapy system.
Financial impact: Expected to reduce non-GAAP EPS by approximately $0.02 in Q4 FY2026 due to near-term integration and commercialization investments, but projected to contribute to long-term revenue growth and margin expansion given its higher gross margin profile.
Integrates home-based diagnostic testing capabilities for sleep, respiratory, and cardiac conditions into ResMed's virtual care ecosystem to simplify and accelerate the patient pathway from evaluation to treatment.
Financial impact: Described as not material to ResMed's consolidated financial results at the time of acquisition, but successfully drove double-digit growth in the Americas mask segment post-acquisition.
Expands ResMed's remote patient monitoring and virtual ward capabilities in the United Kingdom, enhancing digital health offerings across integrated care systems.
Financial impact: Financial terms were not disclosed as the transaction was not material to ResMed's consolidated financial results.
Acquires a leading developer of sleep and respiratory care diagnostics software to streamline physician and sleep lab workflows upstream of ResMed's post-testing AirView and Brightree platforms.
Financial impact: Financial terms were not disclosed as the transaction was not material to ResMed's consolidated financial results.
Strategic Partnerships
Connects consumer-generated wellness insights from the Oura Ring (Gen3 and Oura Ring 4) with ResMed's clinical sleep health resources, helping users identify potential sleep disorders like obstructive sleep apnea (OSA) and transition to professional medical care.
Terms: Undisclosed